A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer

Nab-paclitaxel plus ramucirumab combination therapy shows promising activity and manageable toxicities and could be a useful second-line treatment option for patients with previously treated advanced gastric cancer.